SCHEMBL302163

SCHEMBL302163

O=[C]C(=S)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
CES1 P23141 5/20 0.43
CES2 O00748 4/20 0.43
TSHR P16473 2/20 0.43
DAO P14920 1/20 0.43
NAPRT Q6XQN6 1/20 0.43
MAPT P10636 4/20 0.41
TDP1 Q9NUW8 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
CYP3A4 P08684 2/20 0.40
CA2 P00918 2/20 0.40
CA4 P22748 2/20 0.40
POLB P06746 1/20 0.40
PARP1 P09874 1/20 0.40
CYP2C19 P33261 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CA12 O43570 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4368972 0.76 ALDH1A1 (0.42) ALDH1A1CES1CES2TSHRDAO
SCHEMBL1219464 0.74 ALDH1A1 (0.42) ALDH1A1CES1CES2TSHRDAO
SCHEMBL535862 0.72 CES1 (0.48) ALDH1A1CES1CES2TSHRDAO
SCHEMBL144974 0.70 CES1 (0.52) ALDH1A1CES1CES2TSHRDAO
SCHEMBL314447 0.69
SCHEMBL24662981 0.69 ALDH1A1 (0.39) ALDH1A1CES1CES2TSHRDAO
SCHEMBL15024069 0.69 MAPT (0.39) ALDH1A1CES1CES2TSHRDAO
SCHEMBL6545293 0.69 CES1 (0.39) ALDH1A1CES1CES2TSHRDAO
SCHEMBL8745554 0.68 TDP1 (0.52) ALDH1A1CES1CES2TSHRDAO
SCHEMBL5582134 0.68 TDP1 (0.46) ALDH1A1CES1CES2TSHRDAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4159267-A Novel silyl ester azetidine-2-sulfenate intermediates and process for preparing desacetoxycephalosporins ELI LILLY AND COMPANY (US) 1979-06-26 US claimed
WO-2021074452-A1 COMBINATION PREPARATIONS OF 3-N-FORMYLHYDROXYLAMINOPROPYL PHOSPHONIC ACID DERIVATIVES OR 3-N-ACETYLHYDROXYLAMINOPROPYL PHOSPHONIC ACID DERIVATIVES WITH CLINDAMYCIN AND ARTESUNATE DMG DEUTSCHE MALARIA GMBH (DE) 2021-04-22 WO disclosed
EP-2590651-B1 NEW DRUG COMBINATIONS FOR THE TREATMENT OF MALARIA BIOAGENCY AG (DE) 2018-06-27 EP disclosed
US-20150190418-A1 COMBINATION PREPARATIONS OF 3-N-FORMYL HYDROXY AMINO PROPYL PHOSPHONIC ACID DERIVATIVES OR 3-N-ACETYL HYDROXY AMINO PROPYL PHOSPHONIC ACID DERIVATIVES TOGETHER WITH SPECIAL PHARMACEUTICAL ACTIVE INGREDIENTS JOMAA PHARMAKA GMBH (DE) 2015-07-09 US disclosed
EP-2397475-B1 4, 4' disubstituted 4H-cyclopentadithiophene and new methods for synthesising the same IMEC (BE) 2014-11-12 EP disclosed
US-20130231296-A1 NEW DRUG COMBINATIONS FOR THE TREATMENT OF MALARIA BIOAGENCY AG (DE) 2013-09-05 US disclosed
EP-2590651-A1 NEW DRUG COMBINATIONS FOR THE TREATMENT OF MALARIA BioAgency AG (DE) 2013-05-15 EP disclosed
US-8329923-B2 4, 4′ disubstituted 4H-cyclopentadithiophene and new methods for synthesizing the same IMEC (BE) 2012-12-11 US disclosed
WO-2012004324-A1 NEW DRUG COMBINATIONS FOR THE TREATMENT OF MALARIA BIOAGENCY AG (DE) 2012-01-12 WO disclosed
EP-2404601-A1 New drug combinations for the treatment of Malaria BioAgency AG (DE) 2012-01-11 EP disclosed
EP-1071409-B1 USE OF ORGANOPHOSPHORIC COMPOUNDS FOR THE THERAPEUTIC AND PREVENTATIVE TREATMENT OF INFECTIONS BIOAGENCY AG (DE) 2003-10-15 EP disclosed
EP-1140952-B1 ORGANO-PHOSPHORUS COMPOUNDS AND THEIR UTILIZATION BIOAGENCY AG (DE) 2003-09-03 EP disclosed
US-20030144249-A1 Use of organophosphorous compounds for producing a medicament for treating infections JOMAA PHARMAKA GMBH (DE) 2003-07-31 US disclosed
US-6534489-B1 Organophosphorus compounds and the use thereof JOMAA PHARMAKA GMBH (DE) 2003-03-18 US disclosed
US-20030045746-A1 Phosphorous organic compounds and their use JOMAA PHARMAKA GMBH (DE) 2003-03-06 US disclosed
US-20030036533-A1 Phosphorous organic compounds and their use JOMAA PHARMAKA GMBH (DE) 2003-02-20 US disclosed
EP-1133500-B1 ORGANOPHOSPHOROUS COMPOUNDS AND THE USE THEREOF JOMAA PHARMAKA GMBH (DE) 2002-09-11 EP disclosed
WO-2001094358-A1 ORGANOPHOSPHOROUS HYDROXAMIC ACID DERIVATIVES USED AS HERBICIDES JOMAA PHARMAKA GMBH (DE) 2001-12-13 WO disclosed
US-4159267-A Novel silyl ester azetidine-2-sulfenate intermediates and process for preparing desacetoxycephalosporins ELI LILLY AND COMPANY (US) 1979-06-26 US disclosed
US-3944545-A Process for preparing desacetoxycephalosporins ELI LILLY AND COMPANY (US) 1976-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144249-A1 Use of organophosphorous compounds for producing a medicament for treating infections PHPT1, PPM1D, BPNT1 ALDH1A1 1560/4885CES1 235/4885CES2 474/4885
US-20030045746-A1 Phosphorous organic compounds and their use PPM1D, PFAS, PPM1F ALDH1A1 2555/4885CES1 417/4885CES2 1044/4885
US-20030036533-A1 Phosphorous organic compounds and their use PPM1D, PFAS, PPM1F ALDH1A1 2555/4885CES1 417/4885CES2 1044/4885
US-20130231296-A1 NEW DRUG COMBINATIONS FOR THE TREATMENT OF MALARIA FPR3, PFN1, PFKP ALDH1A1 2730/4885CES1 2634/4885CES2 3101/4885
US-20150190418-A1 COMBINATION PREPARATIONS OF 3-N-FORMYL HYDROXY AMINO PROPYL PHOSPHONIC ACID DERIVATIVES OR 3-N-ACETYL HYDROXY AMINO PROPYL PHOSPHONIC ACID DERIVATIVES TOGETHER WITH SPECIAL PHARMACEUTICAL ACTIVE INGREDIENTS FPR3, FPR1, AANAT ALDH1A1 2096/4885CES1 2607/4885CES2 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.